In: PD-(L)1 x VEGF bispecifics

CS2009

CStone

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan) · press release
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
A cancer drug that hits three targets: two brakes on the immune system (PD-1 and CTLA-4) and VEGF, which feeds the tumour's blood vessels.PD-1/VEGF/CTLA-4 trispecific antibody
How it’s given
“CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 14/21-day cycles (Q2W/Q3W).”In the company’s words, NCT06741644 on ClinicalTrials.gov
Tested for
Advanced Solid Tumors
Main trialPhase 1/2
“This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.”In the company’s words, NCT06741644 on ClinicalTrials.gov

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Jan 2027 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026

Follow CS2009

Following is part of Solo: you see every change to CS2009 the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in